Rare cancers research program will support research on the prevention, detection, diagnosis, and treatment of service members, veterans, their families, and the american public.
Ended Awarded Last action
- Contract number
- HT942525F0245
- Awardee
-
Leidos, Inc. UEI QLNMVC12KWY3 Part of Leidos Holdings, Inc.
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $195,100
Award facts
- Opportunity
-
- Meeting, Programmatic, and Administrative Support Services Pre-Solicitation · W81XWH22R0025 · Posted Aug 16, 2021
- Contract value 93% obligated
- $210,083.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Reston, VA 20190, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $195,100 |
About this award
The Defense Health Agency awarded a delivery order valued at $210,083.88 to Leidos, Inc. (operating as SAIC under its Leidos Services Operating Segment) on June 24, 2025, with performance completion scheduled for June 23, 2026. This cost-plus-fixed-fee contract supports the Rare Cancers Research Program, which focuses on prevention, detection, diagnosis, and treatment research benefiting service members, veterans, their families, and the American public. The work will be performed in Herndon, Virginia. No small business set-aside designation was applied to this award, reflecting Leidos' competitive capabilities as a large, established federal contractor.
This delivery order represents task work under a larger indefinite delivery contract vehicle with the Defense Health Agency. Leidos has demonstrated substantial experience supporting medical research initiatives across federal agencies, including numerous contracts with the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and Defense Health Agency itself for research in cancer, infectious diseases, and rare disease investigations. The parent company, Leidos Holdings, Inc., maintains a broad portfolio of research support services and has secured significant long-term contracts with defense and health-focused agencies, positioning the firm to deliver the scientific and administrative capabilities required for this rare cancers research initiative.
Quick answers
Who was awarded contract HT942525F0245?
HT942525F0245 was awarded to Leidos, Inc. by Defense Health Agency (Department of Defense) on June 24, 2025.
How much is contract HT942525F0245 worth?
The government has obligated $195,100 on HT942525F0245. Its current value, with exercised options, is $210,084.
Is contract HT942525F0245 an order under another contract?
Yes. HT942525F0245 is a delivery order under HT942523D0002, an indefinite delivery contract.
Was contract HT942525F0245 competed?
The extent of competition for HT942525F0245 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award